HIKMA Pharmaceuticals PLC Logo

HIKMA Pharmaceuticals PLC

Develops & markets affordable generic & specialty medicines for markets in NA, MENA, & Europe.

HIK | IL

Overview

Corporate Details

ISIN(s):
GB00B0LCW083
LEI:
549300BNS685UXH4JI75
Country:
United Kingdom
Address:
1 New Burlington Place, W1S 2HR London
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hikma Pharmaceuticals PLC is a multinational generics and specialty pharmaceutical company that develops, manufactures, and markets a broad range of high-quality medicines. For nearly 50 years, its core mission has been to make medications accessible and affordable for patients. The company's portfolio includes branded and non-branded generics, as well as in-licensed products. Hikma serves retail and hospital customers across its primary markets in North America, the Middle East & North Africa (MENA), and Europe, leveraging its manufacturing footprint and local presence to enhance healthcare access.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 13:25
Major Shareholding Notification
Holding(s) in Company
English 69.4 KB
2025-11-11 12:55
Director's Dealing
Director/PDMR Shareholding
English 18.5 KB
2025-11-07 14:10
Director's Dealing
Director/PDMR Shareholding
English 21.3 KB
2025-11-06 08:20
Earnings Release
November Trading Statement
English 23.5 KB
2025-08-22 13:02
Director's Dealing
Director/PDMR Shareholding
English 14.5 KB
2025-08-13 14:51
Director's Dealing
Director/PDMR Shareholding
English 17.9 KB
2025-08-08 13:59
Director's Dealing
Director/PDMR Shareholding
English 14.6 KB
2025-08-07 08:00
Earnings Release
Half-year Report
English 884.0 KB
2025-07-09 10:00
Report Publication Announcement
Notice of Results
English 12.9 KB
2025-07-07 10:16
Report Publication Announcement
Publication of Offering Circular
English 8.0 KB
2025-06-05 15:05
Director's Dealing
Director/PDMR Shareholding
English 14.4 KB
2025-06-03 14:02
Director's Dealing
Director/PDMR Shareholding
English 89.1 KB
2025-05-29 08:00
Capital/Financing Update
Fitch upgrades Hikma to ‘BBB’
English 11.3 KB
2025-05-15 13:00
Earnings Release
Medium-term Group guidance ahead of US site visit
English 12.5 KB
2025-05-08 11:48
Regulatory News Service
S&P upgrades Hikma to ‘BBB’
English 11.3 KB

Automate Your Workflow. Get a real-time feed of all HIKMA Pharmaceuticals PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HIKMA Pharmaceuticals PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HIKMA Pharmaceuticals PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

REGENXBIO Inc. Logo
Developing AAV gene therapies for retinal, metabolic, and neurodegenerative diseases.
United States of America
RGNX
Rein Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel therapies for orphan pulmonary diseases and fibrosis.
United States of America
RNTX
Rekah Pharmaceutical Prod Ltd. Logo
A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.
Israel
REKA
Relay Therapeutics, Inc. Logo
Developing precision medicines for oncology & genetic diseases by analyzing protein motion.
United States of America
RLAY
Repare Therapeutics Inc. Logo
Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.
United States of America
RPTX
Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia
REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden
RESP
REVELATION BIOSCIENCES, INC. Logo
Develops therapies that reprogram the innate immune system to reduce inflammation-related damage.
United States of America
REVB
REVIVA PHARMACEUTICALS HOLDINGS, INC. Logo
Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.
United States of America
RVPH
Revolution Medicines, Inc. Logo
A clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.
United States of America
RVMD

Talk to a Data Expert

Have a question? We'll get back to you promptly.